Nanjing Immunophage Biotech Co., Ltd
Clinical trials sponsored by Nanjing Immunophage Biotech Co., Ltd, explained in plain language.
-
New pill aims to calm Flare-Ups in ulcerative colitis
Disease control Not yet recruitingThis study tests an experimental pill, IPG11406, in 144 adults with moderate to severe ulcerative colitis (UC), a chronic gut condition causing diarrhea and pain. The drug targets immune cells to reduce colon inflammation. Participants receive one of three doses or a placebo for …
Phase: PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug IPG1094 gets first human test in china
Knowledge-focused Not yet recruitingThis phase 1 trial tests the drug IPG1094 in 24 healthy Chinese adults to understand how the body absorbs, processes, and eliminates it. Part A examines whether food affects a single dose, while Part B looks at repeated dosing over 10 days. All participants are monitored for safe…
Phase: PHASE1 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Knowledge-focused
Last updated Jul 02, 2026 05:00 UTC